Nephrology

Back to articles

SHARP: Combination therapy decreases atherosclerotic risk in CKD

KEY POINT

The risk of major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) was reduced with combination cholesterol-lowering treatment in a recent study.